Submit Manuscript

International Journal of Pharmacology

Year: 2021 | Volume: 17 | Issue: 5 | Page No.: 300-307
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Article Trend

Total views 270

Authors

Tarek S. Ibrahim

Tarek S. Ibrahim

Ehab S. Taher

Ahmed E. Altyar

Waleed Y. Rizg

Keywords

Research Article

Novel Levothyroxine HIV-TAT Nanoconjugates Suppressing HeLa Cell Lines Growth in Management of Cervical Cancer

Tarek S. Ibrahim Tarek S. Ibrahim's LiveDNA, Ehab S. Taher, Ahmed E. Altyar and Waleed Y. Rizg
Background and Objective: Thyroid hormones play an important role in normal development, growth and metabolism. Thyroid hormones have been linked to the pathophysiology of different cancer types for over a century, the aim of this work is to potentiation the anticancer activity of L-thyroxine (LT) by conjugating with Trans-Activator of Transcription (TAT) peptide against cervical cancer. Materials and Methods: To enhance the anticancer activity of L-thyroxine (LT) for ovarian cancer cells, LT was conjugated with TAT then characterized for size, Zeta potential and PDI. Biological evaluation as cytotoxicity, cell cycle analysis, annexin-V and caspase-3 were evaluated. Results: The prepared formula was conjugated with HIV-TAT peptide, the prepared formula observed to be in nanometer scale and low PDI size (0.232) with 140.3 nm size. There was a 2.3-fold increase in apoptosis and a 4.3-fold increase in necrosis of the HeLa cells when incubated with the LT-TAT formula when compared to control cells. This increased apoptosis was also associated with increased caspase-3 in treated cells compared to the raw-LT group. Evaluation of cell cycle data showed a substantial arrest of the G2-M phase of the HeLa cells when incubated with LT-TAT NPs. At the same time, a dramatically increased number of pre-G1 cells showed the full apoptotic potential of the LT when administered via the proposed formulation. statistical analysis used in the study was the one-way analysis of variance (ANOVA), followed by the Tukey test. Conclusion: The upregulation of caspase-3 established the superiority of the LT-TAT approach to ovarian cancer. In summary, the outcomes achieved LT-TAT efficient delivery tool for controlling the growth of ovarian cancer cells for improved efficacy.
PDF Fulltext XML References Citation

Leave a Comment

Your email address will not be published. Required fields are marked *